eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
3/2008
vol. 33
 
Share:
Send email
Share:
abstract:

Clinical immunology
Antinuclear antibodies and anti-cyclic citrullinated peptide antibodies in patients treated with adalimumab

Magdalena Szmyrka-Kaczmarek
,
Beata Nowak
,
Jerzy Świerkot
,
Renata Sokolik
,
Arkadiusz Chlebicki
,
Piotr Wiland
,
Jacek Szechiński

(Centr Eur J Immunol 2008; 33 (3): 120-126)
Online publish date: 2008/05/05
View full text Get citation
 

Introduction: Adalimumab is a fully human monoclonal anti-TNF-α antibody used in the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Other available TNF-α inhibitors, such as infliximab (chimeric monoclonal antibody) and etanercept (soluble anti-TNF-α receptor),
can induce the synthesis of autoantibodies and even cause drug-induced lupus. Anti-cyclic citrullinated (anti-CCP) antibodies are highly specific to rheumatoid arthritis and are predictive for rapid progression and erosive disease.

Objective: The aim of the study was to assess the presence of antinuclear antibodies (ANAs) and anti-CCP antibodies in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) before treatment with adalimumab and after 16 weeks of treatment.

Material and Methods: The study group consisted of 10 patients with RA, 7 patients with PsA, and 5 patients with AS. Autoantibodies were measured in their sera before the treatment and after 16 weeks. Antinuclear antibodies were tested by immunofluorescence. Anti-CCP antibodies were detected by
a commercial second-generation ELISA kit. The data analysis included clinical and laboratory response indices.

Results: Antinuclear antibodies were detected in 68% of the patients before treatment and in 54% after 16 weeks of therapy. Although the number of ANA-positive patients was reduced, there was no statistically significant change in their titers. Anti-CCP antibodies were detected in 41% (8 with RA, 1 with AS) of the patients before and in 36% after treatment (all patients with RA). Increases in anti-CCP antibody concentration were observed in 87.5% of the RA patients (P=0.069, Wilcoxon’s test). The mean increase was 77%.
keywords:

antinuclear antibodies (ANAs), anti-cyclic citrullinated peptide (anti-CCP) antibodies, adalimumab, rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.